<産業資料/調査レポートの題名> 2022年6月19日

有効成分の世界市場:製造タイプ別、地域別


◆英文タイトル:Active Pharmaceutical Ingredients Market by Manufacturing Type and Geography - Forecast and Analysis 2020-2024

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Value chain analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY MANUFACTURING TYPE
• Market segmentation by manufacturing type
• Comparison by manufacturing type
• Captive API – Market size and forecast 2019-2024
• Contract API – Market size and forecast 2019-2024
• Market opportunity by manufacturing type
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Asia – Market size and forecast 2019-2024
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Increasing geriatric population
• Paradigm shift in API manufacturing
• Increasing patent expiries
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amneal Pharmaceuticals Inc.
• Cadila Healthcare Ltd.
• Jazz Pharmaceuticals Plc
• Lupin Ltd.
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Vendors: Key offerings
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2019
Exhibit 07: Global market: Size and forecast 2019-2024 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 09: Five forces analysis 2019
Exhibit 10: Five forces analysis 2024
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2019
Exhibit 17: Customer landscape
Exhibit 18: Manufacturing type – Market share 2019-2024 (%)
Exhibit 19: Comparison by manufacturing type
Exhibit 20: Captive API – Market size and forecast 2019-2024 ($ billions)
Exhibit 21: Captive API – Year-over-year growth 2020-2024 (%)
Exhibit 22: Contract API – Market size and forecast 2019-2024 ($ billions)
Exhibit 23: Contract API – Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by manufacturing type
Exhibit 25: Market share by geography 2019-2024 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Asia – Market size and forecast 2019-2024 ($ billions)
Exhibit 28: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 29: Top 3 countries in Asia
Exhibit 30: North America – Market size and forecast 2019-2024 ($ billions)
Exhibit 31: North America – Year-over-year growth 2020-2024 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2019-2024 ($ billions)
Exhibit 34: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: ROW – Market size and forecast 2019-2024 ($ billions)
Exhibit 37: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Cumulative number of DMFs filled 2001-2018
Exhibit 42: Total WLs issued 2010-2014
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Amneal Pharmaceuticals Inc. – Vendor overview
Exhibit 50: Amneal Pharmaceuticals Inc. – Business segments
Exhibit 51: Amneal Pharmaceuticals Inc. – Organizational developments
Exhibit 52: Amneal Pharmaceuticals Inc. – Segment focus
Exhibit 53: Amneal Pharmaceuticals Inc. – Key offerings
Exhibit 54: Amneal Pharmaceuticals Inc. – Key customers
Exhibit 55: Cadila Healthcare Ltd. – Vendor overview
Exhibit 56: Cadila Healthcare Ltd. – Business segments
Exhibit 57: Cadila Healthcare Ltd. – Organizational developments
Exhibit 58: Cadila Healthcare Ltd. – Geographic focus
Exhibit 59: Cadila Healthcare Ltd. – Key offerings
Exhibit 60: Cadila Healthcare Ltd. – Key customers
Exhibit 61: Jazz Pharmaceuticals Plc – Vendor overview
Exhibit 62: Jazz Pharmaceuticals Plc – Business segments
Exhibit 63: Jazz Pharmaceuticals Plc – Organizational developments
Exhibit 64: Jazz Pharmaceuticals Plc – Geographic focus
Exhibit 65: Jazz Pharmaceuticals Plc – Key offerings
Exhibit 66: Jazz Pharmaceuticals Plc – Key customers
Exhibit 67: Lupin Ltd. – Vendor overview
Exhibit 68: Lupin Ltd. – Business segments
Exhibit 69: Lupin Ltd. – Organizational developments
Exhibit 70: Lupin Ltd. – Geographic focus
Exhibit 71: Lupin Ltd. – Key offerings
Exhibit 72: Lupin Ltd. – Key customers
Exhibit 73: Mylan NV – Vendor overview
Exhibit 74: Mylan NV – Product segments
Exhibit 75: Mylan NV – Organizational developments
Exhibit 76: Mylan NV – Geographic focus
Exhibit 77: Mylan NV – Segment focus
Exhibit 78: Mylan NV – Key offerings
Exhibit 79: Mylan NV – Key customers
Exhibit 80: Novartis AG – Vendor overview
Exhibit 81: Novartis AG – Business segments
Exhibit 82: Novartis AG – Organizational developments
Exhibit 83: Novartis AG – Geographic focus
Exhibit 84: Novartis AG – Segment focus
Exhibit 85: Novartis AG – Key offerings
Exhibit 86: Novartis AG – Key customers
Exhibit 87: Pfizer Inc. – Vendor overview
Exhibit 88: Pfizer Inc. – Business segments
Exhibit 89: Pfizer Inc. – Organizational developments
Exhibit 90: Pfizer Inc. – Geographic focus
Exhibit 91: Pfizer Inc. – Segment focus
Exhibit 92: Pfizer Inc. – Key offerings
Exhibit 93: Pfizer Inc. – Key customers
Exhibit 94: Sun Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 95: Sun Pharmaceutical Industries Ltd. – Business segments
Exhibit 96: Sun Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 97: Sun Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 98: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibit 99: Sun Pharmaceutical Industries Ltd. – Key customers
Exhibit 100: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 101: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 102: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 103: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 104: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 105: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 106: Thermo Fisher Scientific Inc. – Vendor overview
Exhibit 107: Thermo Fisher Scientific Inc. – Business segments
Exhibit 108: Thermo Fisher Scientific Inc. – Organizational developments
Exhibit 109: Thermo Fisher Scientific Inc. – Geographic focus
Exhibit 110: Thermo Fisher Scientific Inc. – Segment focus
Exhibit 111: Thermo Fisher Scientific Inc. – Key offerings
Exhibit 112: Thermo Fisher Scientific Inc. – Key customers
Exhibit 113: Validation techniques employed for market sizing
Exhibit 114: Definition of market positioning of vendors


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark